CAMEL NANOBODY-BASED B7-H3 CAR-T CELLS WITH HIGH EFFICACY AGAINST SOLID TUMORS
نویسندگان
چکیده
Abstract Background and significance Chimeric antigen receptor (CAR)-T cell therapy shows promising potency for treating patients with hematological malignancies. However, follow-up data indicate that only 30% to 50% of these experience long-term disease control. In solid tumors, the B7-H3 transmembrane protein is an emerging target harbors in its ectodomain two distinct epitope motifs - IgC IgV. Here, we developed nanobody-based CAR-T strategy targeting investigated anti-tumor efficacy xenograft mouse models. Methods We isolated anti-B7-H3 VHHs from our large dromedary camel VHH nanobody libraries great diversity (> 1012 total) by phage display technology. The binding was validated ELISA, flow cytometry, Octet. A peptide library synthesized predict select VHHs. Anti-tumor effect cells determined via luciferase-based killing assay as well Two tumor models, human neuroblastoma pancreatic adenocarcinoma, were used present study. Single-cell transcriptome RNA sequencing coupled single T-cell functional proteomics analysis analyze functionality cells. Results analyzed isoforms at levels 4IgB7-H3 a therapeutic dominant isoform tumors. Targeting 4Ig isoform, obtained panel high-affinity nanobodies cross-reactive human, mouse, rat, monkey. Furthermore, demonstrated based on had potent antitumor activity against tumors rigorous T signaling significant infiltration. Mechanistically, uncovered top-upregulated genes might be critical persistence polyfunctional microenvironment. Conclusions Our results provide novel product use therapy.
منابع مشابه
B7-h3-specific engager T cells for the immunotherapy of pediatric solid tumors
Background B7-H3 positive tumors, including osteosarcoma, neuroblastoma, and high grade glioma, cause significant morbidity and mortality despite aggressive multimodality treatments. Current B7-H3-targeted immune-therapies take advantage of the monoclonal antibody 8H9, which is actively being evaluated in Phase I clinical trials. Engager T cells, which secrete bispecific engager molecules consi...
متن کاملTargeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)
Neuroblastoma is the most common non-CNS tumor in children. Poor prognosis for patients presenting with highrisk disease underlines the need for novel therapeutic strategies. Chimeric antigen receptor T cell (CART) therapies combine the epitope specificity of a monoclonal antibody with the cytotoxicity of an activated T cell, and have demonstrated clinical efficacy in pediatric leukemia. To exp...
متن کاملPrognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis
Increasing evidence suggests B7-H3 is aberrantly expressed in various cancers, though its prognostic significance in solid tumors remains controversial. We therefore performed a meta-analysis to clarify the prognostic value of B7-H3 expression in human solid tumors. The PubMed and Embase databases were searched, and 28 studies involving 4623 patients were ultimately included in the analysis. Ha...
متن کاملMurine B7-H3 is a negative regulator of T cells.
T cell activation is regulated by the innate immune system through positive and negative costimulatory molecules. B7-H3 is a novel B7-like molecule with a putative receptor on activated T cells. Human B7-H3 was first described as a positive costimulator, most potently inducing IFN-gamma production and cellular immunity. In this study we examined the expression and function of mouse B7-H3. B7-H3...
متن کاملNew Strategies for the Treatment of Solid Tumors with CAR-T Cells
Recent years, we have witnessed significant progresses in both basic and clinical studies regarding novel therapeutic strategies with genetically engineered T cells. Modification with chimeric antigen receptors (CARs) endows T cells with tumor specific cytotoxicity and thus induce anti-tumor immunity against malignancies. However, targeting solid tumors is more challenging than targeting B-cell...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Antibody therapeutics
سال: 2023
ISSN: ['2516-4236']
DOI: https://doi.org/10.1093/abt/tbad014.005